Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Inclusion Criteria: * Patients must have histologically or cytologically confirmed advanced biliary/pancreatic cancer, urothelial cancer, or non-small cell lung cancer that is metastatic or unresectable * Patients with known CNS metastases should be excluded from this clinical trial * ECOG performance status ≤ 2 (Karnofsky ≥ 60%) * Life expectancy of greater than 12 weeks * Absolute neutrophil count ≥ 1,500/mcL * Platelets ≥ 100,000/mcL * Total bilirubin within normal institutional limits * AST/ALT ≤ 2.5 times institutional upper limit of normal * Creatinine within normal institutional limits OR creatinine clearance ≥ 60 mL/min * QTc interval on ECG ≤ 0.48 seconds by Bazett's calculation (≤ CTCAE v.4 grade 2) * Not pregnant or nursing * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation * Patients must be able to swallow pills and have no significant impairment in gastrointestinal absorption * Patients with known or suspected germline mutation in BRCA1 or BRCA2 are eligible to participate * Patients in study screening (primarily those with pancreatic cancer) who have a family history that is suspicious for BRCA1 or BRCA2 germline mutation should be assessed by the BRCAPRO computer program to quantitate the likelihood of harboring a deleterious BRCA mutation * Patients found to have a BRCAPRO probability score of ≥ 20% …